JP2020524166A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524166A5
JP2020524166A5 JP2019570553A JP2019570553A JP2020524166A5 JP 2020524166 A5 JP2020524166 A5 JP 2020524166A5 JP 2019570553 A JP2019570553 A JP 2019570553A JP 2019570553 A JP2019570553 A JP 2019570553A JP 2020524166 A5 JP2020524166 A5 JP 2020524166A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
methyl
deficiency
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019570553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524166A (ja
JP7208931B2 (ja
Filing date
Publication date
Priority claimed from GBGB1709824.5A external-priority patent/GB201709824D0/en
Priority claimed from GBGB1803561.8A external-priority patent/GB201803561D0/en
Application filed filed Critical
Priority claimed from PCT/GB2018/051691 external-priority patent/WO2018234775A1/en
Publication of JP2020524166A publication Critical patent/JP2020524166A/ja
Publication of JP2020524166A5 publication Critical patent/JP2020524166A5/ja
Application granted granted Critical
Publication of JP7208931B2 publication Critical patent/JP7208931B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019570553A 2017-06-20 2018-06-19 Dub阻害剤としての活性をもつ置換シアノピロリジン類 Active JP7208931B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1709824.5A GB201709824D0 (en) 2017-06-20 2017-06-20 Novel Compounds
GB1709824.5 2017-06-20
GB1803561.8 2018-03-06
GBGB1803561.8A GB201803561D0 (en) 2018-03-06 2018-03-06 Novel compounds
PCT/GB2018/051691 WO2018234775A1 (en) 2017-06-20 2018-06-19 Substituted cyanopyrrolidines with activity as dub inhibitors

Publications (3)

Publication Number Publication Date
JP2020524166A JP2020524166A (ja) 2020-08-13
JP2020524166A5 true JP2020524166A5 (cg-RX-API-DMAC7.html) 2021-08-05
JP7208931B2 JP7208931B2 (ja) 2023-01-19

Family

ID=62778943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570553A Active JP7208931B2 (ja) 2017-06-20 2018-06-19 Dub阻害剤としての活性をもつ置換シアノピロリジン類

Country Status (5)

Country Link
US (1) US11059809B2 (cg-RX-API-DMAC7.html)
EP (1) EP3642196B1 (cg-RX-API-DMAC7.html)
JP (1) JP7208931B2 (cg-RX-API-DMAC7.html)
CN (1) CN110831936B (cg-RX-API-DMAC7.html)
WO (1) WO2018234775A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522267D0 (en) * 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
US11014912B2 (en) 2016-09-27 2021-05-25 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
KR102717600B1 (ko) 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. 유비퀴틴 특이적 펩티다제 30의 억제
CA3098628A1 (en) 2018-05-17 2019-11-21 Forma Therapeutics, Inc. Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
PT3860989T (pt) 2018-10-05 2023-06-30 Forma Therapeutics Inc Pirrolinas fundidas que atuam como inibidores da protease 30 específica da ubiquitina (usp30)
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Usp30阻害剤としての活性を有する置換n-シアノピロリジン
WO2023149768A1 (ko) * 2022-02-07 2023-08-10 주식회사 내쉬원 탈유비퀴틴화효소 억제제를 포함하는 소포체 스트레스 관련 질환 예방 또는 치료용 약학적 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001256981A1 (en) 2000-04-06 2001-10-23 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
WO2008151183A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
UY31299A1 (es) 2007-08-20 2009-03-31 Nuevos inhibidores de catepsina y su uso
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
UY31770A1 (es) 2008-04-18 2009-09-30 Inhibidores de catepsina c
CL2009000914A1 (es) 2008-04-18 2010-04-16 Glaxo Group Ltd Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
SG11201600159TA (en) 2013-07-31 2016-02-26 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
WO2015179190A1 (en) 2014-05-19 2015-11-26 Northeastern University N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof
WO2015183987A1 (en) * 2014-05-27 2015-12-03 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
JP6708661B2 (ja) * 2015-03-30 2020-06-10 ミッション セラピューティクス リミティド Usp30阻害剤としての1−シアノ−ピロリジン化合物
EP3800186B1 (en) 2015-07-14 2024-10-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) * 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
JP6959252B2 (ja) 2016-03-24 2021-11-02 ミッション セラピューティクス リミティド Dub阻害剤としての1−シアノピロリジン誘導体
US11014912B2 (en) 2016-09-27 2021-05-25 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses

Similar Documents

Publication Publication Date Title
JP2020524166A5 (cg-RX-API-DMAC7.html)
JP2019532938A5 (cg-RX-API-DMAC7.html)
JP2019533659A5 (cg-RX-API-DMAC7.html)
JP2019503362A5 (cg-RX-API-DMAC7.html)
JP2019501142A5 (cg-RX-API-DMAC7.html)
JP2018524367A5 (cg-RX-API-DMAC7.html)
JP2019532950A5 (cg-RX-API-DMAC7.html)
JP2020521730A5 (cg-RX-API-DMAC7.html)
US20240246915A1 (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
US20180265524A1 (en) Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
ES2400070T3 (es) Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
JP2019532945A5 (cg-RX-API-DMAC7.html)
JP2019518766A5 (cg-RX-API-DMAC7.html)
JP6076498B2 (ja) ナンセンス突然変異抑制剤としてのピリミド[4,5−b]キノリン−4,5(3h,10h)−ジオン
JP7328323B2 (ja) SMARCA2/BRM ATPase阻害剤としての尿素化合物及び組成物
JP2019504009A5 (cg-RX-API-DMAC7.html)
WO2010115836A4 (en) Substituted piperidines as ccr3 antagonists
KR20180058829A (ko) Ezh2 억제제로 수모세포종을 치료하는 방법
JP6343034B2 (ja) ナフチリジンジオン誘導体
US20150218148A1 (en) Benzothiazole Or Benzoxazole Compounds As Sumo Activators
TW202313050A (zh) 組合療法
ES2728932T3 (es) Compuestos orgánicos
US9896448B2 (en) Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives
CN101193878A (zh) 实体肿瘤治疗剂
CN101193877A (zh) 造血系统肿瘤治疗剂